← All trials
NCT01502306
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2012
- Primary completion
- Feb 1, 2014
- Completion date
- Feb 1, 2014
- First posted
- —
- Last posted
- —
- Enrollment
- 3819
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- University of California, San DiegoLead sponsor
- University of California, San DiegoOverall official - principal investigator
- University of California, San DiegoReponsible party - principal investigator
- University of California, San FranciscoCollaborator
- California Department of Public HealthCollaborator
- California Department of Health ServicesCollaborator
- Centers for Medicare and Medicaid ServicesCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.